Vanguard Amendment: Reports 0 Shares in Mesa Laboratories
Mesa Laboratories Inc — Schedule 13G/A (Amendment No. 6) by The Vanguard Group.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Mesa Laboratories Inc — Schedule 13G/A (Amendment No. 6) by The Vanguard Group. The filing states that The Vanguard Group reports zero shares beneficially owned of Mesa Laboratories common stock and 0% of the class. The amendment explains an internal realignment effective January 12, 2026 that caused certain Vanguard subsidiaries or divisions to report separately and disaggregated from The Vanguard Group, Inc. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Insights
Vanguard disaggregated holdings; this filing reports no beneficial ownership in Mesa Laboratories.
The amendment clarifies that an internal realignment on January 12, 2026 led certain Vanguard subsidiaries or business divisions to report beneficial ownership separately, in reliance on SEC Release No. 34-39538. The filing explicitly reports 0 shares and 0% ownership.
Cash‑flow treatment and any subsidiary holdings are not described in this excerpt; subsequent filings by the disaggregated entities may show holdings if present.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Mesa Laboratories (MLAB) Schedule 13G/A by Vanguard state?
Why did Vanguard file Amendment No. 6 for MLAB?
Who signed the Schedule 13G/A amendment for Vanguard and when?
Does the amendment change Vanguard’s investment strategy in MLAB?
AI-generated analysis. How Rhea-AI works. Not financial advice.